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SHORT COMMUNICATION
Growth inhibitory and cytotoxic effects of melatonin and its
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It has been shown in a number of experimental studies that
the pineal gland and, more specifically, the pineal indole
hormone melatonin, can modulate tumour growth. Most of
these resports (for example, Narita & Kudo, 1985; Regelson
& Pierpaoli, 1987) refer to experimentally induced mammary
carcinomas in rodents. Interestingly, while tumour growth
inhibition following in vivo administration of melatonin has
most frequently been described, there are also reports of
tumour growth stimulation by the hormone (Hamilton, 1969;
Stanberry et al., 1983). Similarly, Meyskens & Salmon
(1981), when describing the in vitro response of clonogenic
melanoma cells from patients to melatonin, reported stimu-
lation of colony formation in two of 11 cases, no effect in
samples from three patients and a decrease in total cloning
efficiency with increasing concentrations of melatonin in the
remaining six cases. This activity of melatonin has been
variously ascribed to a direct cell killing effect on the cancer
cells, an inhibitory effect on pituitary hormones involved in
mammary cancer, a regulation of polyamine synthesis or
pteridine metabolism or an immunomodulatory role (Ebels,
1980; Fraschini et al., 1980; Lissoni et al., 1987). Although
melatonin undoubtedly has an influence on tumour develop-
ment, interest in its bioactivity has, until recently, centred
almost entirely on its effects on reproduction. The presence
of gonadal melatonin receptors suggests that melatonin can
directly affect the gonads and thereby alter reproductive
status (Cohen et al., 1978). In view of these data, we decided
to investigate whether melatonin and a series of other
naturally occurring pineal indoles could directly suppress the
growth of ovarian carcinoma cell lines in vitro.
Melatonin was first isolated from bovine pineal glands in
1969 (Lerner et al., 1969) and its chemical structure was
determined. It was found to have (see Figure 1) a very short
biological half-life and an N-acetyl and a 5-methoxy group
are considered structural requirements for its bioactivity.
Since the C5 and C6 positions of melatonin are the sites of
metabolic activity, the block of one or both of these sites
should result in an analogue with an increased half-life.
Melatonin can be metabolised by two main routes (Young et
al., 1985): (i) by 6-hydroxylation to form 6-hydroxymelatonin
and (ii) by demethylation to form N-acetyl-serotonin (see
Figure 1). Our initial laboratory investigations appeared to
be consistent with these facts since they indicated that while
melatonin (N-acetyl-5-methoxytryptamine) and N-acetyl-
serotonin (N-acetyl-5-hydroxytryptamine) exerted significant
in vitro growth inhibition against both SK-OV-3 and JA-1
ovarian carcinoma cell lines only at relatively high concen-
trations of approximately 0.5-1.0m$ml-1, two other pineal
methoxyindoles, 5-methoxytryptamine (5-methyl-serotonin)
and 6-hydroxymelatonin, proved approximately five times
more effective and 5,6'-dihydroxytryptamine (a synthetic
compound of similar structure to a structural isomer of 6-
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hydroxymelatonin) appeared at least 10 times more potent
(Leone et al., 1988).
We have now confirmed these observations (see Table I)
and in addition quantitated the cytotoxic effects of these
compounds on the SK-OV-3 cells using soft agar clonogenic
cell survival assays (Courtenay & Mills, 1978) (see Figure 2).
These survival assays used conditions of continuous exposure
of the cells to the test compounds, which were added into
the agar. The IC50 concentrations (i.e. those required to
reduce survival by 50% of control, solvent-treated cells)
ranged from 16 to 940jgml-1. These values correspond well
with those derived from growth inhibition assays, after 72h
in vitro incubation of the cells plus test compound (see Table
I). Thus it would appear that these compounds have definite
cytotoxic and not just cytostatic effects, as judged by the
longer term clonogenic assay data. One of the major
problems in using these compounds was their relative lack of
solubility in aqueous solvents. This accounts for the range
and, in some cases large s.e. values, of the figures quoted in
Table I.
In this present study, we have also evaluated these indoles
against two other human tumour cell lines, not of ovarian
origin, namely the RT112 line derived from a transitional
carcinoma of the bladder (Masters et al., 1986) and the
MCF-7 cell line derived from an adenocarcinoma of the
breast (Soule et al., 1973). In terms of growth inhibition,
melatonin and N-acetyl serotonin exerted very similar effects
on all the cell lines tested (see Table I). The other four
compounds, however, proved considerably more growth
inhibitory against the RT112 cells, as opposed to the other
three cell lines. We therefore have no evidence that any of
these compounds exerted any preferential growth inhibitory
effects against ovarian carcinoma cells in vitro. We failed to
observe any inhibition of cell growth in our MCF-7 cells at
low concentrations of melatonin within the range of 10-8 to
10-10M, as reported recently (Blask & Hill, 1986; Hill &
Blask, 1988). However, since these authors attributed these
effects to a complex interaction with hormones such as
oestradiol and prolactin, this apparent discrepancy may be
explained by differing experimental conditions using serum-
containing medium and/or the source of the actual MCF-7
cells used of which there are many, as reviewed recently
(Osborne et al., 1987).
We showed previously (Leone et al., 1988) by GCMS (gas
chromatography mass spectometry) analysis that two of the
most active compounds in vitro, namely 6-hydroxymelatonin
and 5,6'-dihydroxytryptamine, were very poorly solubilised
and the former compound also proved very unstable both at
4°C and at 37°C under our in vitro assay conditions. Indeed,
6-hydroxymelatonin exerted significant cytotoxicity at barely
detectable levels (i.e. <1jIg) obtained by GCMS analysis. In
an attempt to identify melatonin derivatives that were readily
water soluble and stable at 37°C, we next tested the 6-
sulphate and 6-glucuronide conjugates of melatonin meta-
bolites, normally formed in the liver and rapidly excreted in
the urine. These conjugates were isolated from rat urine as
described earlier by Leone et al. (1987). The 6-sulphatoxy-
melatonin proved totally inactive in inhibiting the growth of
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Figure 1 The biosynthetic pathway of the pineal indole hormone melatonin.
Table I Growth inhibitory effects of melatonin and various melatonin metabolites and related
compounds, following a 72-h continuous exposure in vitro, on four human tumour cell lines
GI50 values (pgml-')
SK-OV-3 cells JA cells RTJ12 cells MCF-7 cells
Test compounds? (Mean+ s.e.)b Meanc (Range) (Mean)d (Mean)
Melatonin 505+134 371 (312-480) 525 400
(450)C
N-Acetyl serotonin 538+88 455 (380-530) 325 200
(940)C
5-Methoxytryptamine 158+36 112 (91-125) 39 130
(125)Cr
6-Hydroxymelatonin 165+78 120 (100-140) 20 305
(125)C
Tryptamine hydrochloride 79+14 100 (80-120) 24 100
(65)C
5,6-Dihydroxytryptamine 18+2 18 (17-19) 4 23
(16)e
aThe molecular weights of the test compounds are as follows: melatonin 232; N-acetyl serotonin 218;
5-methoxytryptamine 190; 6-hydroxymelatonin 248; tryptamine hydrochloride 197 and 5,6'-
dihydroxytryptamine 177; bMean of at least 3 individual experiments; cMean of 2-3 individual
experiments; dMean of 2 individual experiments; IC.50 values derived from colony-forming assay data
shown in Figure 2.
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Figure 2 Survival of SK-OV-3 cells assessed by colony
formation in soft agar with continuous exposure to melatonin
(0 O), N-acetyl serotonin (----*), 6-hydroxymelatonin
(A / ), 5-methoxytryptamine (A---A), tryptamine
hydrochloride (* *) and 5,6-dihydroxytryptamine
([L LE). Each point represents the mean of at least two
estimations + s.e.
either JA-1 or SK-OV-3 cells at concentrations up to
I mgml-, and although on one occasion growth inhibition
was noted with the extracted 6-glucuronide conjugate (Leone
et al., 1988), this effect was not reproducible when further
samples of this metabolite isolated from urine were tested
(Leone et al., 1987) or when the synthetic material
(unpublished method, A.M. Leone) was evaluated at concen-
trations up to 100pgml-1.
These data therefore indicate that one of the primary
metabolites of melatonin, namely 6-hydroxymelatonin
appears to exert significantly greater cytotoxicity than
melatonin itself, but any potential usefulness as an anti-
tumour agent is severely limited by its poor solubility and
instability in aqueous solution. However, in view of the
anecdotal reports of benefit of melatonin in early clinical
trials of some human tumours, reviewed recently (Regelson
& Pierpaoli, 1987), and the fact that it can be administered
in vivo with extremely low toxicity towards normal tissues
(i.e. 3-6g of melatonin have been given orally daily for one
month with minimal side-effects (Papavasiliou et al., 1972)),
it may prove worthwhile to attempt to identify or synthesise
more stable analogues of 6-hydroxymelatonin.
The authors are grateful to Drs R.E. Silman and A.M. Leone from
the Department of Reproductive Physiology, St Bartholomew's
Hospital Medical College, London, for providing the various
melatonin metabolites and related compounds for use in this study.
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